Table 1 Patient, mission and airway characteristics

Total (n = 425)

225

200

Gender

 Male

142 (63.1%)

115 (57.7%)

Age

 median (IQR)

6.4 (2.4–12.7)

5 (1.7–10.5)

NACA

 III

1 (0.4%)

1 (0.5%)

 IV

31 (13.8%)

75 (37.5%)

 V

116 (51.6%)

116 (58%)

 VI

43 (19.1%)

8 (4%)

 VII

34 (15.1%)

0

GCS

 < 9

206 (91.5%)

184 (92%)

 > = 9

19 (8.5%)

16 (8%)

Trauma

151 (67.1%)

69 (34.5%)

 Craniofacial injury

117 (77.5%)

55 (79.7%)

 Other

34 (22.5%)

14 (20.3%)

Non-trauma

74 (32.9%)

131 (65.5%)

 Neurological

20 (27%)

40 (30.5%)

 Respiratory

37 (50%)

12 (9.2%)

 Circulatory

13 (17.6%)

53 (40.5%)

 Other

4 (5.4%)

26 (19.8%)

Airway (final)

 NIV

4 (1.8%)

5 (2.5%)

 Tracheotomy (pre-existing)

3 (1.3%)

5 (2.5%)

 Orotracheal int.

212 (94.2%)

172 (86%)

 Nasotracheal int.

0

18 (9%)

 Laryngeal mask

2 (0.9%)

0

 Laryngeal tube

3 (1.3%)

0

 CICV

1 (0.4%)

n/a

Neuromuscular blocking agents used (NACA III-V)

129/148 (87.2%)

n/a

 Rocuronium

34 (26.4%)

 Suxamethonium

95 (73.6%)

Neuromuscular blocking agents used (NACA VI-VII)

11/77 (13.3%)

n/a

 Rocuronium

6 (54.5%)

 Suxamethonium

5 (45.5%)